# Efficacy and Safety of Camrelizumab Combined With Nab-Paclitaxel Plus Gemcitabine for Metastatic Pancreatic Cancer

> **NCT04498689** · PHASE2 · UNKNOWN · sponsor: **Fudan University** · enrollment: 117 (estimated)

## Conditions studied

- Metastatic Pancreatic Cancer

## Interventions

- **DRUG:** Camrelizumab
- **DRUG:** Nab paclitaxel
- **DRUG:** Gemcitabine Injection

## Key facts

- **NCT ID:** NCT04498689
- **Lead sponsor:** Fudan University
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2019-08-01
- **Primary completion:** 2022-12-31
- **Final completion:** 2022-12-31
- **Target enrollment:** 117 (ESTIMATED)
- **Last updated:** 2020-08-04


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04498689

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04498689, "Efficacy and Safety of Camrelizumab Combined With Nab-Paclitaxel Plus Gemcitabine for Metastatic Pancreatic Cancer". Retrieved via AI Analytics 2026-05-25 from https://api.ai-analytics.org/clinical/NCT04498689. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*